News

The Phase II trial is designed to compare a four-week dose-ranging regimen of once-daily oral SP-333 (1mg, 3mg and 6mg) against placebo in patients taking opioid analgesics for

The Phase III trial showed that EYLEA 2mg in both treatment groups (dosed monthly or every two months), showed a sustained improvement from baseline in best corrected visual

ACEON is an angiotensin converting enzyme (ACE) inhibitor approved for the treatment of patients with high blood pressure (hypertension) and reduce the risk of heart attack in patients

The US Food and Drug Administration (FDA) had approved DALVANCE in May 2014 and it was the first drug to be approved as a Qualified Infectious Disease Product

Enrollment into four dose groups has been completed (25, 50, 100 and 150 mg) and no drug related adverse events have been reported. The fifth dose group (225

"Our new antibody platform Ylanthia is being used in a rising number of therapeutic relationships including our recent alliances with Merck Serono and Temple University. In addition to

The Butrans Transdermal System is also approved to allow the use of two patches to facilitate dose adjustments during titration. The total dose from both patches should not

Specifically, clinical study CTH-105 will be initiated per the proposal submitted to the FDA under the Company´s Investigational New Drug (IND) application. APL-130277 is an easy-to-administer, fast-acting reformulation

The allowed patent, which is published as US Patent Application 20140072615, is based on Agile’s prior patent, US 7,384,650, covering the formulation for Twirla. "We believe the allowance